LETTERS FOR ISSUE ON
|
|
|
- Rolf Cannon
- 6 years ago
- Views:
Transcription
1 S FOR ISSUE ON BIOLOGICAL DIVISION S. NO. NAME OF COMPANY DY. NO STATUS 1 M/S LV PRASAD EYE INSTITUTE ACKNOWLEDGE 2 M/S PFIZER LTD APPROVAL 3 M/S GSK ASIA PVT, LTD APPROVAL 4 M/S BHARAT SERUM AND VACCINE LTD CLARIFICATION 5 M/S MYLAN LABORATORIES LTD 17318, APPROVAL & CLARIFICATION 6 M/S CADILA PHARMACEUTICALS LTD CONTINUATION MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS
2 1. THE COMMISSIONER, GANDHINAGAR (CLAA) THE DEPUTY DRUGS CONTROLLER, AHMEDABAD (CLAA) (M/S. HYGEIA ORTHO PVT. LTD., AHMEDABAD) FTS. NO APPROVAL SUBSEQUENT NEW DRUG S. NO. NAME OF THE FIRM REFERENCE NO. FTS NO. TYPE OF 1. M/S CIPLA - - SEC 2. M/S SUN - - SEC 3. M/S LYKA LABS LTD., - - SEC 4. M/S EMCURE PHARMACEUTICALS - - SEC LTD 5. M/S PANACEA BIOTEC LTD., - - SEC 6. M/S UNITED BIOTECH (P) LTD., - - SEC 7. M/S ALKEM - - SEC 8. M/S ABBOTT INDIA LTD., - - SEC 9. M/S BHARAT SERUM AND VACCINES LTD., - - SEC 10. M/S UNIMED TECHNOLOGY LTD., - - SEC 11. M/S RUSAN - - SEC 12. M/S NOVARTIS - - SEC 13. M/S SUN - - SEC 14. M/S MANKIND PHARMA LIMITED., DEFICIENCY 15. M/S CELON LABORATORIES LTD., DEFICIENCY 16. M/S PAVIOUR PHARMACEUTICALS PRIVATE LIMITED., DEFICIENCY 17. M/A ABBOTT INDIA LTD., DEFICIENCY SHELF LIFE S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. MILAN LABORATRIES INDIA PVT. LTD. NIL GLOBAL CLINICAL TRIAL
3 SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. MANIPAL ACUNOVA 2 M/S. MAYA CLINICALS EXPORT NOC APPROVAL NEW SITES APPROVAL `3 M/S. NOVO NORDISK - MINUTES OF MEETING LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. AMANTA HEALTHCARE LTD., GUJARAT QUERY 02 M/S. WINTAC LTD., BANGALORE QUERY 03 M/S. BERYL DRUGS LTD., M. P. QUERY 04 M/S. ULTRA LABORATORIES PVT. LTD.., KERALA QUERY BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT. LTD., NAVI MUMBAI M/S. AG RESEARCH PRIVATE LIMITED, HYDERABAD M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA APPROVAL APPROVAL APPROVAL
4 4. M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA M/S. ALKEM LABORATORIES LTD., TALOJA , TAL: PANVEL, DIST: RAIGAD APPROVAL APPROVAL APPROVAL 7. M/S. APOTEX RESEARCH PVT. LTD., BANGALORE CLARIFICATION 8. M/S. ATHENA DRUG DELIVERY SOLUTIONS PVT. LTD., DIST. THANE, MAHARASHTRA M/S. CADILA PHARMACEUTICAL LTD., DHOLKA , AHMEDABAD APPROVAL APPROVAL 10. M/S. CIPLA LIMITED, MUMBAI APPROVAL 11. M/S. CIPLA LIMITED, MUMBAI APPROVAL 12. M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD M/S. EMCURE PHARMACEUTICALS LIMITED, PUNE M/S. GLENMARK PHARMACEUTICALS LTD., NAVI MUMBAI APPROVAL APPROVAL APPROVAL APPROVAL APPROVAL 17. M/S. HETERO LABS LTD., HYDERABAD CLARIFICATION 18. M/S. LAMBDA THERAPEUTIC RESEARCH LTD., AHMEDABAD M/S. LAMBDA THERAPEUTIC RESEARCH LTD., AHMEDABAD CLARIFICATION APPROVAL 20. M/S. LIFESAN CLINICAL RESEARCH, MUMBAI REJECTION
5 21. M/S. LOTUS LABS PVT. LTD., BANGALORE TEST LICENCE 22. M/S. LOTUS LABS PVT. LTD., BANGALORE CLARIFICATION 23. M/S. LOTUS LABS PVT. LTD., CHENNAI APPROVAL 24. M/S. LUPIN LIMITED (RESEARCH PARK), PUNE APPROVAL 25. M/S. LUPIN LIMITED (RESEARCH PARK), PUNE APPROVAL 26. M/S. LUPIN LIMITED (RESEARCH PARK), PUNE APPROVAL 27. M/S. LUPIN LIMITED (RESEARCH PARK), PUNE APPROVAL 28. M/S. LUPIN LIMITED (RESEARCH PARK), PUNE APPROVAL 29. M/S. MACLEODS PHARMACEUTICALS LTD., ANDHERI (EAST), MUMBAI M/S. MACLEODS PHARMACEUTICALS LTD., ANDHERI (EAST), MUMBAI APPROVAL APPROVAL 31. M/S. MANIPAL ACUNOVA LTD., MANGALORE TEST LICENCE 32. M/S. MANIPAL ACUNOVA LTD., MANGALORE TEST LICENCE 33. M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., HARYANA 34. M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., HARYANA 35. M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SYNGENE INTERNATIONAL LTD., BANGALORE M/S. TORRENT PHARMACEUTICALS LTD. (RESEARCH CENTRE), GUJARAT APPROVAL APPROVAL APPROVAL APPROVAL 2699 APPROVAL APPROVAL
6 39. M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD APPROVAL APPROVAL 41. M/S. VIMTA LABS LTD., HYDERABAD CLARIFICATION
Indian Pharmaceutical Formulations Industry Report,
Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more
Second Meeting of CII National Committee on Pharmaceuticals Friday, 03 November 2017: 1430 hrs-1400 hrs CII Central Office, New Delhi
Second Meeting of National Committee on Pharmaceuticals 2017-18 Friday, 03 November 2017: 1430 hrs-1400 hrs Central Office, New Delhi MINUTES OF THE MEETING The second meeting of National Committee on
Bird s Eye View of Indian Pharma
Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy
Indian Active Pharmaceutical Ingredients (APIs) Industry Report,
Indian Active Pharmaceutical Ingredients (APIs) Industry Report, 2008-2009 India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR
Dispatch from India. Marine Drive, Mumbai
Dispatch from India Marine Drive, Mumbai Dear Friends: It is the start of Monsoon season in Mumbai, and torrential rains recently snarled traffic in the city. But that hasn't slowed down the frenetic pace
Contract(s) Quoted by ICB. Project Name: Second National Tuberculosis Control Project (SNTCP) Country: India, Credit No IN
Contract(s) Quoted by ICB Project Name: Second National Tuberculosis Control Project (SNTCP) Country: India, Credit 4228-IN Bid/Contract Reference : RITES/MSM/EPW/SNTCP/03/2010 opened on 17.09.2010 Scope
IPCA Laboratories Ltd Result Update: Q3 FY 11
IPCA Laboratories Ltd Result Update: Q3 FY 11 C.M.P: Rs.282.40 Target Price: Rs.325.00 Date: March 10 th 2011 BUY Stock Data: Sector: Pharma Face Value Rs. 2.00 52 wk. High/Low (Rs.) 350.00/233.00 Volume
New peaks. Domestic Formulations
August 2011 Thematic Report Sector: Pharmaceuticals Domestic Formulations New peaks Nimish Desai (NimishDesai@MotilalOswal.com); Tel: +91 22 3982 5406 Amit Shah (Amit.Shah@MotilalOswal.com); Tel: +91 22
COMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 3 METHODOLOGY AND INFORMATION SOURCES... 3 ANALYST CREDENTIALS...
GlaxoSmithKline Pharmaceuticals Limited Annual Analyst Meet, September 2017
GlaxoSmithKline Pharmaceuticals Limited Annual Analyst Meet, 2017 1 September 2017 GlaxoSmithKline Pharmaceuticals Limited Analyst Update 1 September 2017 A. Vaidheesh, Managing Director Andrew Aristidou,
Is the tide turning positive? Lupin step in the right direction. 8 July
8 July 216 Healthcare Motilal Oswal values your support in the Asiamoney Brokers Poll 216 for India Research, Sales and Trading team. We request your ballot. Pharma coverage universe Company TP (INR) %
PHARMA INDUSTRY ISSUES IN INCOME-TAX. Presentation by: Abhitan Mehta. November 4, 2017
PHARMA INDUSTRY ISSUES IN INCOME-TAX November 4, 2017 Presentation by: Abhitan Mehta Major Issues Freebies Scientific Research Expense Stockist Restructuring Remuneration to Doctors 192 v. 194J 2 FREEBIES
A Study on comparative Financial Status of selected companies of Indian Pharmaceutical Industry using Efficiency ratios
A Study on comparative Financial Status of selected companies of Indian Pharmaceutical Industry using Efficiency ratios CA. T.A Nikita Ph.D Scholar, GLS University, Ahmedabad, Gujarat ABSTRACT Performance
Financial Predictors Influencing the Ranking of Indian Pharmaceutical Companies 2016
International Journal of Accounting, Finance and Risk Management 2016; 1(1): 39-45 http://www.sciencepublishinggroup.com/j/ijafrm doi: 10.11648/j.ijafrm.20160101.16 Financial Predictors Influencing the
To Measure the Liquidity Of Selected Private Sector Pharmaceutical Companies in India
To Measure the Liquidity Of Selected Private Sector Pharmaceutical Companies in India Dr.K.Ayappan Assistant Professor, Government Arts College (Autonomous),Kumbakonam Abstract: The Indian pharmaceuticals
A Study on Impact of EVA, Value of Firm and Cost of Capital as Per NI Approach on the Share Price of Pharmaceutical Industry
A Study on Impact of EVA, Value of Firm and Cost of Capital as Per NI Approach on the Share Price of Pharmaceutical Industry Mantrark Mehta Assistant Professor at Shri Chimanbhai Patel Institute of Management
CHAPTER VII FINDINGS AND CONCLUSIONS
CHAPTER VII FINDINGS AND CONCLUSIONS The study in general aims at studying the impact of dividend policy on shareholders wealth of selected pharma units in India. This study covers eleven companies viz.,
BUY AJANTA PHARMA LTD. CMP Target Price JAN. 28 th 2014 SYNOPSIS. Result Update: Q3 FY14
BUY CMP 940.00 Target Price 1025.00 AJANTA PHARMA LTD. Result Update: Q3 FY14 JAN. 28 th 2014 ISIN: INE031B01031 Index Details Stock Data Sector Pharmaceutical BSE Code 532331 Face Value 5.00 52wk. High
Research Chronicler: International Multidisciplinary Peer-Reviewed Journal ISSN: Print: ISSN: Online: X
Corporate Drift to Financial Distress: Analysis of Mumbai Based Pharmaceutical Companies Pritish Behera Guest Faculty, Dept. of Business Management, Central University of Orissa, Koraput, (Odisha) India
Dealtracker Providing M&A and Private Equity deal insights
Dealtracker Providing M&A and Private Equity deal insights April 2015 Volume 11.4 Disclaimer This document captures the list of deals announced based on information available in the public domain and based
Item No : Requests for extension of validity of formal approvals
Supplementary Agenda for the 66 th meeting of the Board of Approval to be held on 27 th August, 2015, in the Room No. 47, Udyog Bhawan, New Delhi Item No. 66.10 : Requests for extension of validity of
Research Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Financial Performance Analysis of Sun Pharma. V Srinivasa Kumar*, R Renganathan, C Vijaya Banu, and V Vijaya Anand. Faculty at School
[To be published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii)]
![[To be published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii)]](/thumbs/80/81436949.jpg "[To be published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii)]")
Notification No.58/2014-Customs (N.T.) subsection (1) of section 5 of the Customs Act, 1962 (52 of 1962), the Board of Excise and Customs hereby appoints the Additional Commissioner or Joint Commissioner
Institutional Equities
Sector Update Pharmaceutical Sector 1 October 218 Prescription Charts of Interest September 218 Dr. Reddy s Laboratories During the quarter, the company gained strength in Aloxi while it continues to maintain
Peer Groups CMP Market Cap EPS P/E (x) P/BV(x) Dividend Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
HOLD CMP 115.00 Target Price 126.00 NEULAND LABORATORIES LTD Result Update: Q4 FY13 July 8 th, 2013 ISIN: INE794A01010 Index Details Stock Data Sector Pharmaceuticals BSE Code 524558 Face Value 10.00 52wk.
Amended Notice Inviting Tender
INDIAN INSTITUTE OF TECHNOLOGY ISM),DHANBAD Amended Notice Inviting Tender Reference No. HC-INS-130-18-19 Date: 05.09.2018 Pre-Bid meeting held on dated 26.09.2018 No.: HC-INS-130-18-19 Date: - 28.09.2018
Lupin Ltd Result Update: Q3 FY 11
Lupin Ltd Result Update: Q3 FY 11 C.M.P: Rs.416.30 Target Price: Rs.479.00 Date: April 2 nd 2011 BUY Stock Data: Sector: Pharma Face Value Rs. 2.00 52 wk. High/Low (Rs.) 519.80/319.81 Volume (2 wk. Avg.)
Financial year-wise FDI Equity Inflows:
(ii) Financial year-wise FDI Equity : Financial Year (Apr-Mar) Amount of FDI Equity %age growth over the in Rupees Crore in US$ million previous year 2000-01 10,733 2,463-2001-02 18,654 4,065 ( + ) 65
PFIZER LIMITED Result Update (PARENT BASIS): Q1 FY15
PFIZER LIMITED Result Update (PARENT BASIS): Q1 FY15 ISIN: INE182A01018 SEPTEMBER 29 th,2014 Recommendation BUY CMP 1634.05 Target Price 1797.00 STOCK DETAILS Sector BSE Code 500680 Face Value 10.00 Pharmaceuticals
Sanofi India ACCUMULATE. Performance Highlights. CMP `4,410 Target Price `4,738. 1QCY2016 Result Update Pharmaceutical. 3-year price chart
1QCY2016 Result Update Pharmaceutical May 5, 2016 Sanofi India Performance Highlights Y/E Dec. (` cr) 1QCY2016 4QCY2015 % chg (qoq) 1QCY2015 % chg (yoy) Net sales 506 522 (3.1) 460 10.1 Other income 64
MUMBAI OBSTETRIC & GYNECOLOGICAL SOCIETY DETAILS OF NET WORTH & INTEREST APPROPRIATION MADE DURING THE YEAR 01/04/2011 TO 31/03/2012
MUMBAI OBSTETRIC & GYNECOLOGICAL SOCIETY DETAILS OF NET WORTH & INTEREST APPROPRIATION MADE DURING THE YEAR 01/04/2011 TO 31/03/2012 PARTICULAR RS. Total Interest recd. 1,722,585.35 Interest transferred
ISSN: (Online) Volume 3, Issue 7, July 2015 International Journal of Advance Research in Computer Science and Management Studies
ISSN: 2321-7782 (Online) Volume 3, Issue 7, July 2015 International Journal of Advance Research in Computer Science and Management Studies Research Article / Survey Paper / Case Study Available online
F I R S T C A L L BUY R E S E A R C H AVENTIS PHARMA LTD
C.M.P: Rs.1806.00 Stock Data Sector AVENTIS PHARMA LTD 1 Year Comparative Graph Pharmaceuticals Face Value (Rs.) 10.00 52 wk. High/Low (Rs.) 2059.00/1474.00 Volume (2 wk. Avg.) 1265 BSE Code 500674 Market
Pharmaceuticals. 2QFY19 Results Preview. 10 Oct Amey Chalke
Pharmaceuticals FY19 Results Preview 10 Oct 2018 Amey Chalke amey.chalke@hdfcsec.com +91-22-6171-7321 Eshan Desai eshan.desai@hdfcsec.com +91-22-6639-2476 3QFY17 4QFY17 1QFY18 FY18 3QFY18 4QFY18 1QFY19
OFFICE OF THE COMMISSIONER OF CENTRAL EXCISE CHENNAI II COMMISSIONERATE 692 MHU COMPLEX NANDANAM CHENNAI-35. Trade Notice No: 8/2004 Dated:.1.
OFFICE OF THE COMMISSIONER OF CENTRAL EXCISE CHENNAI II COMMISSIONERATE 692 MHU COMPLEX NANDANAM CHENNAI-35 Trade Notice No: 8/2004 Dated:.1.2004 Sub: Communication of Notification Reg. Please find enclosed
MINUTES OF THE 78 th MEETING OF DRUGS TECHNICAL ADVISORY BOARD HELD ON 12 TH FEBRUARY, 2018 AT DGHS, NIRMAN BHAWAN, NEW DELHI
MINUTES OF THE 78 th MEETING OF DRUGS TECHNICAL ADVISORY BOARD HELD ON 12 TH FEBRUARY, 2018 AT DGHS, NIRMAN BHAWAN, NEW DELHI PRESENT 1. Dr. B.D. Athani, Chairman Director General of Health Services, Nirman
Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months
3QCY2017 Result Update Pharmaceutical November 20, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 3QCY2017 2QCY2017 % chg (qoq) 3QCY2016 % chg (yoy) Net sales Other income Operating profit 627
Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart.
2QCY2017 Result Update Pharmaceutical August 28, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 2QCY2017 1QCY2017 % chg (qoq) 2QCY2016 % chg (yoy) Net sales Other income Operating profit 556
Span Diagnostics Limited
Span Diagnostics Limited Date: 5 th January, 216 Stock Performance Details Shareholding Details October 215 Current Price : ` 96.7^ Face Value : ` 1 per share 52 wk High / Low : ` 96.9 / 42.55 Total Traded
Q3 FY 2013 Earnings Update. Q2 FY 2013 Earnings Update
1 Q3 FY 2013 Earnings Update Q2 FY 2013 Earnings Update Safe Harbour No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness
PUBLIC ANNOUNCEMENT UNDER REGULATION 15(1) OF THE SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011
PUBLIC ANNOUNCEMENT UNDER REGULATION 15(1) OF THE SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 Open Offer ( Open Offer / Offer ) by Sun Pharmaceutical Industries Limited ( Sun
Sanofi India NEUTRAL. Performance Highlights. CMP `4,301 Target Price - 4QCY2016 Result Update Pharmaceutical. Investment Period - 3-year price chart
4QCY2016 Result Update Pharmaceutical March 10, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 4QCY2016 3QCY2016 % chg (qoq) 4QCY2015 % chg (yoy) Net sales 552 583 (5.3) 522 5.6 Other income
CIRCULAR. Circular No Circular Date Regulatory and Compliance. Derivatives. Category. Segment
CIRCULAR Circular No. 20190228-4 Circular Date 20190228 Category Regulatory and Compliance Segment Derivatives Subject Revised Combined Futures &Options Position Limits for Single Stock Derivatives. Attachments
Jenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /
Can Fin Homes Ltd. at a glance
Can Fin Homes Ltd. at a glance 26 years of vision, passion and progress and offering home loans since 1987..and it is just a beginning Information to investors as of 31/12/13 About us Legacy Focus 26 year
1. Setting up of ICD at Modi Nagar U.P. by Kribhco Infrastructure Ltd.(File No. 16/18/2010-Infra 1)
Minutes of the meeting of Inter Ministries Committee(IMC) for consideration of proposals for setting up of ICDs/CFSs held under the Chairmanship of Shri M. Prasad, Additional Secretary (Infrastructure),
FDI SYNOPSIS ON COUNTRY U.K. (as on )
Table No. 6.1.A.(iv): CUMULATIVE FDI INFLOWS: FDI SYNOPSIS ON COUNTRY U.K. (as on 31.12.2010) Cumulative FDI equity all Countries in India during the period from January 2000 to December 2010 are US$ 127.00
EY Tax Alert. Executive summary
23 July EY Tax Alert Government issues Notifications to restrict benefit in respect of CVD exemption for certain goods under exemption notifications, to domestic manufacturers Executive summary Tax Alerts
Surcharge and education cess cannot be levied on the tax deducted at source based on Section 206AA of the Act
1 February 2017 Surcharge and education cess cannot be levied on the tax deducted at source based on Section 206AA of the Act Background Recently, the Delhi Bench of the Income-tax Appellate Tribunal (the
The brief profile of M/s. Kalyaniwalla & Mistry LLP, Chartered Accountants, is enclosed herewith.
SEC/SE/105/17-18 Chennai, July 28, 2017 The Listing Department National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai 400 051 Sub: Ref: Appointment of M/s. Kalyaniwalla
Q4 FY 2013 Earnings Update. Q2 FY 2013 Earnings Update
1 Q4 FY 2013 Earnings Update Q2 FY 2013 Earnings Update Safe Harbour No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness
Strategic CSR through Healthcare: A Case study on Indian Pharmaceutical Companies
Strategic CSR through Healthcare: A Case study on n Pharmaceutical Companies Susanta Datta 1 &Vinayak Karande 2 Abstract n Pharmaceutical sector contributed 2.4%in global pharmaceutical business in terms
Pharmaceuticals. 4QFY18 Results Preview. 13 Apr Amey Chalke
Pharmaceuticals FY18 Results Preview 13 Apr 2018 Amey Chalke amey.chalke@hdfcsec.com +91-22-6171-7321 1QFY17 2QFY17 3QFY17 FY17 1QFY18 2QFY18 3QFY18E 1QFY17 2QFY17 3QFY17 FY17 1QFY18 2QFY18 3QFY18E PHARMACEUTICALS
Regulatory environment pertaining to Import of Gold dore in India James Jose Secretary, Association of Gold Refineries & Mints
Regulatory environment pertaining to Import of Gold dore in India James Jose Secretary, Association of Gold Refineries & Mints CGR Metalloys Pvt. Ltd., Cochin, India 1 Effective 1.6.2018, Director general
Customer Grievance Redressal Mechanism
Customer Grievance Redressal Mechanism Date: March 21, 2018 Version: 2 0 P a g e Contents 1. Customer Complaint/Query Resolution Process & System... 2 2. Customer Touch Points to register Complaints/Queries...
Indian Healthcare Industry
Indian Healthcare Industry 2012 Synopsis Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics Pvt. Ltd. (Gyan). While
How to control the rising cost of medicines in Europe
How to control the rising cost of medicines in Europe Dr Andrew Hill Department of Translational Medicine, University of Liverpool, UK Sofia, Bulgaria, March 6 th 2018 How cheaply can medicines be produced?
Gems & Jewellery 10 hectares with built up processing area of 50,000 sq metres.
Minutes of the 2nd Board of Approval meeting held on 12 th June, 2006 at 10.30 A.M. under the Chairmanship of Shri Gopal K. Pillai, Special Secretary, Department of Commerce to consider proposals for setting
CUSTOMS NOTIFICATION (No. 105 to 121) N.T. SERIES
CUSTOMS (No. 105 to 121) N.T. SERIES NO.105/2009-CUSTOMS (N.T.) Central Excise and Customs, New Central excise Building, Opposite Gandhi Baugh, Chowk Bazar, Surat-I to act as a common adjudicating authority
BDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
Sakar Healthcare Private Limited
Ratings Sakar Healthcare Private Limited Facilities Amount (Rs. crore) Ratings 1 Remarks Long-term Bank Facilities 18.48 (reduced from 20.30) CARE BBB- (Triple B Minus) Reaffirmed Short-term Bank Facilities
CASE No. 103 of CASE No. 104 of 2016
Before the MAHARASHTRA ELECTRICITY REGULATORY COMMISSION World Trade Centre, Centre No.1, 13th Floor, Cuffe Parade, Mumbai 400005. Tel. 022 22163964/65/69 Fax 22163976 Email: mercindia@merc.gov.in Website:
ANALYSIS OF FINANCIAL PERFORMANCE OF PHARMACEUTICAL COMPANIES USING Z SCORE MODEL
ANALYSIS OF FINANCIAL PERFORMANCE OF PHARMACEUTICAL COMPANIES USING Z SCORE MODEL 1 Dr. M. Muthu Gopalakrishnan & 2 Sathish A.J, A.Prakash Reddy and U.Rama Krishna 1 Associate Professor, Faculty of Accoutnign
Hetero Drugs Limited
Hetero Drugs Limited January 17, 2017 Ratings Long-term Bank Long-term/ Short-term Bank Amount 355 (enhanced from 311.10) 320 Rating 1 CARE A+; Stable (Single A Plus; Outlook: Stable) CARE A+; Stable/
Fact Sheet Consolidated Financial data, First Quarter,
Profit and Loss Account summary for the (As per Indian GAAP) In Rs. crore, except per share data Particulars June 30, 2006 2005 Growth (%) March 31, 2006 Growth % in Q1 FY 2007 over Q4 FY 2006 Income from
Alembic BUY. Performance Highlights. Target Price. 1QFY2011 Result Update Pharmaceutical. Investment Period 12 months
1QFY2011 Result Update Pharmaceutical August 2, 2010 Alembic Performance Highlights Y/E March (Rs cr) 1QFY2011 4QFY2010 % chg (qoq) 1QFY2010 % chg (yoy) Net Sales 279 267 4.6 291 (4.0) Other Income 1 1
Apollo Hospitals (APOHOS) 1280
Result Update Rating matrix Rating : Hold Target : 134 Target Period : 12 months Potential Upside : 5% What s Changed? Target Changed from 14 to 134 EPS FY16E Changed from 3.9 to 28.9 EPS FY17E Changed
PwC ReportingInBrief. Amendments to Ind AS 20, Accounting for Government Grants and Disclosure of Government Assistance
PwC ReportingInBrief Amendments to Ind AS 20, Accounting for Government Grants and Disclosure of Government Assistance In brief The Ministry of Corporate Affairs (MCA) notified the Companies (Indian Accounting
PHARMACEUTICALS Drug pricing probe: Storm in a teacup?
SECTOR UPDATE PHARMACEUTICALS Drug pricing probe: Storm in a teacup? India Equity Research Pharmaceuticals The US presidential election has fueled much populist debate on drug pricing, beating down pharma
EMCURE PHARMACEUTICALS LIMITED
EMCURE PHARMACEUTICALS LIMITED Ratings Facilities Amount (Rs. crore) Long-term Bank Facilities 507.89 (reduced from 542.80) Short-term Bank Facilities 115.04 (reduced from 117) Long/Short-term Bank Facilities
Indiabulls Real Estate Limited
Indiabulls Real Estate Limited Investor Presentation 25 th April, 2018 Financial Performance Key Financial Highlights: FY 17-18 IBREL Consolidated FY 17-18 FY 16-17 Revenue from Operations ( Cr) 5,926.5
GlaxoSmithKline Pharmaceuticals
3QFY2017 Result Update Pharmaceutical February 15, 2017 GlaxoSmithKline Pharmaceuticals Performance Highlights Y/E Mar (` cr) 3QFY2017 2QFY2017 % chg (QoQ) 3QFY2016 % chg (YoY) NEUTRAL CMP `2,683 Target
Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route
Aurum Equity Partners LLP Aurum Insights Pharmaceuticals October 2014 Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route Read more
January 2013 Volume 9.1. Dealtracker. Providing M&A and Private Equity Deal Insights. Grant Thornton India LLP. All rights reserved.
Volume 9.1 Dealtracker Providing M&A and Private Equity Deal Insights Feb-1 Mar-1 Apr-1 May-1 Jun-1 Jul-1 Aug-1 Sep-1 Oct-1 Nov-1 Dec-1 Jan-13 Value (US$bn) Number of Deals Dealtracker Deal Round Up 94
Sharing insights. News Alert 19 April, 2011
www.pwc.com/in Sharing insights News Alert 19 April, 2011 Expenditure on voluntary retirement scheme is tax deductible even if the scheme is not in accordance with the exemption provision for the employees
Quarterly Issue Volume 9.3. Dealtracker. Providing M&A and Private Equity Deal Insights. Grant Thornton India LLP. All rights reserved.
Quarterly Issue Volume 9. Dealtracker Providing M&A and Private Equity Deal Insights Dealtracker Quarter 1, 201: Deal Snapshot Quarter 1 Deal Summary Q1 Deal Summary Year 2011 2012 201 2011 2012 201 Domestic
Neuland Labs BUY RESULTS REVIEW 1QFY19 12 AUG 2018
RESULTS REVIEW 1QFY19 12 AUG 2018 Neuland Labs INDUSTRY PHARMA CMP (as on 10 Aug 2018) Rs 687 Target Price Rs 914 Nifty 11,430 Sensex 37,869 KEY STOCK DATA Bloomberg NLL IN No. of Shares (mn) 17 MCap (Rs
ALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
Staying Updated Customs, FTP and WTO newsletter
Staying Updated, FTP and WTO newsletter November 2015: Volume 18 Issue 08 In the issue In the issue The Central Government has notified Village Tumb, Taluka Umbergaon, District Valsad in State of Gujarat
40 per cent of the global profit to Indian PE is attributed based on the functions performed, assets deployed and risk assumed
27 April 2017 40 per cent of the global profit to Indian PE is attributed based on the functions performed, assets deployed and risk assumed Background The Bengaluru Bench of Income-tax Appellate Tribunal
Healthcare AUGUST For updated information, please visit
1 Contents Advantage India Market overview and trends Growth drivers Success stories: Apollo Hospitals, Fortis Opportunities Useful information 2 Advantage India Strong demand revenue in India is set to
Latin Manharlal Securities Pvt Ltd. 124 Viraj, S,V.Road, Khar (W), Mumbai S t o c k I d e a
S t o c k I d e a Date: 28-Dec -12 CMP: `126 TARGET: `189 Upside: 50% B U Y SENSEX 19445 NIFTY 5908 Eq. Cap. (` Crs) 53.85 Face Value (`) 10.0 M. Cap (` Crs) `679 BSE Code 511676 NSE Code Financial Year
Prof. Claude Farrugia Vice President Communications, EIPG
Prof. Claude Farrugia Vice President Communications, EIPG Is the storm over? Malta, 2008 Is the storm over? Malta, 2008 Is the storm over? Malta, 2008 Drug Development is Risky Drug Development is a Costly
EY Tax Alert. Executive summary. Bangalore Tribunal rules on deductibility of employee share reward discount cross-charged by foreign parent company
22 October 2013 2013mber 2012 EY Tax Alert Bangalore Tribunal rules on deductibility of employee share reward discount cross-charged by foreign parent company Executive summary Tax Alerts cover significant
Clarification on applicability date of formats for financial results and intimation of reasons for delay in submission of financial results
IFRS Notes Clarification on applicability date of formats for financial results and intimation of reasons for delay in submission of financial results 7 December 2018 KPMG.com/in IFRS NOTES 7 December
Determinants of Capital structure with special reference to indian pharmaceutical sector: panel Data analysis
Article can be accessed online at http://www.publishingindia.com Determinants of Capital structure with special reference to indian pharmaceutical sector: panel Data analysis Abstract m.s. ramaratnam*,
Sun Pharma BUY. Performance Highlights. `783 Target Price `944 CMP. 1QFY2017 Result Update Pharmaceutical. Investment Period 12 months
1QFY2017 Result Update Pharmaceutical August 17, 2016 Sun Pharma Performance Highlights (` cr) 1QFY2017 4QFY2016 % chg QoQ 1QFY2016 % chg yoy Net sales 8,007 7,414 8.0 6,527 22.7 Other income 393 185 112.3
Quasi capital transaction, not an interest simplictor and notional interest adjustment deleted
2 May 2017 Quasi capital transaction, not an interest simplictor and notional interest adjustment deleted Background Recently, the Ahmedabad Bench of the Income-tax Appellate Tribunal (the Tribunal) in
Ascendas India Trust Supplementary Information As at 31 March 2018
OVERVIEW AS AT 31 DECEMBER 2017 Ascendas India Trust Supplementary Information As at 31 March 2018 Contents Overview Portfolio breakdown 2 Portfolio history 2 Lease expiry profile 2 Portfolio Floor area
Indian CRAMS Industry. Steel. The. otel. Pesticides. Tracto. nking Express Service. Power Generation Pa. Hospital Industry. Express Service Cr
inum Banking Cement Commercial Vehicle Cotton & Cotton Ya Business Process Management (BPM) Construction Educat Chlor-Alkali Renewable Energy Crude Oil Gems & J o Component pparel Industry oal Natural
Sharing insights. News Alert 23 May, Payment made for airborne geophysical survey services is not FTS. In brief. Facts.
www.pwc.com/in Sharing insights News Alert 23 May, 2012 Payment made for airborne geophysical survey services is not FTS In brief In the recent case of De Beers India Minerals Pvt. Ltd. 1 (the assessee),
Staying Updated Indirect tax newsletter
Staying Updated Indirect tax newsletter September 2015, Volume 18 Issue 06 In the issue In the issue Manufacture Aluminium dross and ash emerging as by-products during the diecasting of aluminium parts
Glenmark Pharmaceuticals Ltd (GNP)
December 13, 2011 Company Update CMP : INR 292 Rating : Buy Target : INR 385 KEY DATA Market Cap (INR bn) 79.2 Market Cap (USD mn) 1494.9 52 WK High / Low 372 / 241 Avg Daily Volume (NSE) 575958 Face Value
Whether supply of goods with transportation services - naturally bundled and treated as composite supply.
25 th J U N E 2018 This alert summaries the following writ petitions & AAR filed and outcome of such petitions. The key issues raised before the courts and Authority for Advance Ruling are : AAR Ruling
CORPORATE UPDATE IN THIS ISSUE DIRECT TAX INTERNATIONAL TAXATION TRANSFER PRICING DOMESTIC TAXATION. September, 2018
CORPORATE UPDATE DIRECT TAX INTERNATIONAL TAXATION I. High Court upholds grossing up for withholding tax purpose where taxes are borne by customer on fees for technical services paid to non-resident even
Companies (Indian Accounting Standards) (Amendment) Rules, 2016
www.pwc.in Companies (Indian Accounting Standards) (Amendment) Rules, 2016 June 2016 News alert Background The Ministry of Corporate Affairs (MCA) notified the Companies (Indian Accounting Standards) (Amendment)
We value your family s health as much as you do.
Future Health Suraksha We value your family s health as much as you do. Presenting a wide network of hospital tie-ups across the nation. Family Plan Call us at: 1800-220-233, 1860-500-3333, 022-6783 7800
Sharing insights. News Alert 24 January, Discussion paper on presence of foreign banks in India Regulatory Alert. Overview.
www.pwc.com/in Sharing insights News Alert 24 January, 2011 Discussion paper on presence of foreign banks in India Regulatory Alert Overview Setting the ball rolling for the foreign banks presence in India,
BANK OF MAHARASHTRA Head Office ल कम गल, 1501, श व ज नगर, पणण -5. A. Terms of Sale:
ब क ऑफ महह रह ष प रधह न कह रह र य लर BANK OF MAHARASHTRA Head Office ल कम गल, 1501, श व ज नगर, पणण -5 LOKMANGAL,1501.SHIVAJINAGAR,PUNE-5 Recovery Department TELE : 020-25539884 / 25530268 / 25520001 e-mail:
Infomerics Valuation And Rating Pvt. Ltd.
Press Release Rating Instrument / Facility Proposed Paper Commercial Unimed Technologies Ltd. December 31, 2018 Amount Rating 500.00 Provisional IVR A1+ (SO) (Provisional IVR A One Plus (Structured Obligation))